These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25538279)

  • 1. Mineralocorticoid receptors: an appealing target to treat coronary microvascular dysfunction in diabetes.
    Bender SB; Jia G; Sowers JR
    Diabetes; 2015 Jan; 64(1):3-5. PubMed ID: 25538279
    [No Abstract]   [Full Text] [Related]  

  • 2. Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes.
    Garg R; Rao AD; Baimas-George M; Hurwitz S; Foster C; Shah RV; Jerosch-Herold M; Kwong RY; Di Carli MF; Adler GK
    Diabetes; 2015 Jan; 64(1):236-42. PubMed ID: 25125488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus.
    Joffe HV; Kwong RY; Gerhard-Herman MD; Rice C; Feldman K; Adler GK
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2552-8. PubMed ID: 17488800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes and heart failure: epidemiology, pathophysiology and management.
    Desai AS; O'Gara PT
    Indian Heart J; 2005; 57(4):295-303. PubMed ID: 16350674
    [No Abstract]   [Full Text] [Related]  

  • 5. Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient.
    Karagiannis A; Tziomalos K; Dona K; Pyrpasopoulou A; Kartali N; Athyros V; Zamboulis C
    QJM; 2005 Dec; 98(12):913-5. PubMed ID: 16299060
    [No Abstract]   [Full Text] [Related]  

  • 6. Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension.
    Oxlund CS; Cangemi C; Henriksen JE; Jacobsen IA; Gram J; Schousboe K; Tarnow L; Argraves WS; Rasmussen LM
    J Hum Hypertens; 2015 Jan; 29(1):28-32. PubMed ID: 24739800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients.
    Davies J; Gavin A; Band M; Morris A; Struthers A
    Br J Clin Pharmacol; 2005 May; 59(5):520-3. PubMed ID: 15842549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2 diabetes mellitus.
    Silva MA; Cau SB; Lopes RA; Manzato CP; Neves KB; Bruder-Nascimento T; Mestriner FL; Montezano AC; Nguyen Dinh Cat A; Touyz RM; Tostes RC
    Clin Sci (Lond); 2015 Oct; 129(7):533-45. PubMed ID: 25967696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The use of rheopolyglucin in diabetic patients with a microcirculatory disorder].
    Zhumatova MG
    Ter Arkh; 1991; 63(10):49-51. PubMed ID: 1725224
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluating the efficacy of mineralocorticoid receptor antagonism in patients with STEMI without heart failure.
    Scirica BM
    Eur Heart J; 2014 Sep; 35(34):2276-8. PubMed ID: 24780613
    [No Abstract]   [Full Text] [Related]  

  • 11. Homocysteine concentrations in patients with diabetes mellitus--relationship to microvascular and macrovascular disease.
    Elias AN; Eng S
    Diabetes Obes Metab; 2005 Mar; 7(2):117-21. PubMed ID: 15715884
    [No Abstract]   [Full Text] [Related]  

  • 12. Spironolactone made no difference to patients with mild diastolic heart failure.
    BMJ; 2013 Feb; 346():f1290. PubMed ID: 23447350
    [No Abstract]   [Full Text] [Related]  

  • 13. An unmet medical need vs. regulatory recommendations: how should we treat patients with hyperaldosteronism and advanced chronic kidney disease when surgery is not feasible?
    Mikačić I
    Eur J Clin Pharmacol; 2020 Jan; 76(1):131-132. PubMed ID: 31664474
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral Spironolactone for Acne Vulgaris in Adult Females: An Update of the Literature.
    Barker RA; Wilcox C; Layton AM
    Am J Clin Dermatol; 2020 Apr; 21(2):303-305. PubMed ID: 32166709
    [No Abstract]   [Full Text] [Related]  

  • 15. Adding low-dose spironolactone to multidrug regimens for resistant hypertension.
    Berecek KH; Farag A; Bahtiyar G; Rothman J; McFarlane SI
    Curr Hypertens Rep; 2004 Jun; 6(3):211-2. PubMed ID: 15128473
    [No Abstract]   [Full Text] [Related]  

  • 16. Beneficial impact of spironolactone in diabetic nephropathy.
    Schjoedt KJ; Rossing K; Juhl TR; Boomsma F; Rossing P; Tarnow L; Parving HH
    Kidney Int; 2005 Dec; 68(6):2829-36. PubMed ID: 16316360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary microvascular function is independently associated with left ventricular filling pressure in patients with type 2 diabetes mellitus.
    Kawata T; Daimon M; Miyazaki S; Ichikawa R; Maruyama M; Chiang SJ; Ito C; Sato F; Watada H; Daida H
    Cardiovasc Diabetol; 2015 Aug; 14():98. PubMed ID: 26242308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?
    Bomback AS; Kshirsagar AV; Klemmer PJ
    Nat Clin Pract Nephrol; 2009 Feb; 5(2):74-5. PubMed ID: 19029998
    [No Abstract]   [Full Text] [Related]  

  • 19. Diabetes mellitus and coronary microvascular function in asymptomatic patients with severe aortic stenosis and nonobstructed coronary arteries.
    Banovic M; Brkovic V; Nedeljkovic I; Nedeljkovic M; Popovic D; Djordjevic-Dikic A; Ristic A; Nikolic S; Beleslin B
    Diab Vasc Dis Res; 2016 May; 13(3):220-7. PubMed ID: 26993497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of the renin-angiotensin system improves cerebral microcirculatory perfusion in diabetic hypertensive rats.
    Estato V; Obadia N; Carvalho-Tavares J; Freitas FS; Reis P; Castro-Faria Neto H; Lessa MA; Tibiriçá E
    Microvasc Res; 2013 May; 87():41-9. PubMed ID: 23466285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.